PetMed Express, Inc. Form 10-K Summary
Business Context and Reporting Period
PetMed Express, Inc. operates PetMeds and PetCareRx, direct-to-consumer online pet pharmacies and retailers offering prescription and non-prescription medications, food, supplements, supplies, memberships, telehealth, insurance and related services. The filing covers the fiscal year ended March 31, 2024, with comparable fiscal 2023 results. Although the request references 2023 Q4, the filing’s fourth quarter ended March 31, 2024.
PetCareRx was acquired on April 3, 2023 for approximately $36.1 million in cash. The acquisition expanded the product catalog, added membership revenue and contributed approximately 286,000 customers.
Financial Performance and Liquidity
| Metric | Fiscal 2024 | Fiscal 2023 | Change |
|---|---|---|---|
| Net sales | $281.1 million | $256.6 million | Up 9.5% |
| Gross profit | $78.6 million | $70.7 million | Up 11.2% |
| Gross margin | 28.0% | 27.6% | Up 40 bps |
| Operating income/(loss) | $(8.2) million | $6.1 million | Declined |
| Net income/(loss) | $(7.5) million | $5.1 million | Declined $12.6 million |
| Adjusted EBITDA | $8.2 million | $19.8 million | Down 58% |
| Net cash from operating activities | $4.3 million | $27.8 million | Down $23.5 million |
Fiscal 2024 sales included $247.0 million of reorder sales, $24.3 million of new-order sales and $9.8 million of membership fees. The average order value was approximately $94, compared with $93 in fiscal 2023. Approximately 53.5% of fourth-quarter net sales were generated through AutoShip, compared with 44.4% in the prior-year quarter.
Operating expenses increased materially: general and administrative expense rose 32.4% to $55.2 million, advertising expense increased to $24.5 million, and depreciation and amortization increased to $7.1 million, including approximately $2.0 million of amortization related to PetCareRx intangibles. Customer acquisition cost increased to approximately $81 from $71.
At March 31, 2024, cash and cash equivalents were $55.3 million, compared with $104.1 million at March 31, 2023. Working capital declined to approximately $21.5 million from $72.9 million. Cash was primarily used for the PetCareRx acquisition, the Vetster investment, capital expenditures and dividends. The Company had no debt obligations and no material outstanding purchase or lease commitments.
Fourth-quarter net loss was $5.0 million, compared with a $0.2 million loss in the prior-year quarter. Fourth-quarter adjusted EBITDA was $0.5 million, compared with $3.6 million. The filing does not provide a clear fourth-quarter revenue or gross-margin value in the supplied text.
Material Changes Versus the Prior Comparable Period
- PetCareRx added approximately $24.5 million of fiscal 2024 sales, including membership fees, but also increased operating costs, amortization and integration expenses.
- Gross margin improved modestly because of the higher-margin membership revenue and acquisition-related mix.
- Operating results shifted from profit to loss as general and administrative, advertising and depreciation and amortization expenses grew faster than gross profit.
- Operating cash flow fell substantially, while investing cash outflows increased to $40.7 million, primarily because of the PetCareRx acquisition.
- The quarterly dividend was suspended indefinitely in February 2024. Fiscal 2024 dividends totaled $12.7 million, or $0.60 per share, versus $25.3 million, or $1.20 per share, in fiscal 2023.
- Prior-period financial statements and quarterly information were restated for sales-tax accruals and the valuation of PetCareRx-related deferred tax assets and goodwill. The Company recorded approximately $26.0 million of cumulative sales-tax liability as of March 31, 2023.
Guidance, Outlook, Risks and Unusual Items
The Company did not provide formal numerical revenue or earnings guidance. Management’s fiscal 2025 priorities are to consolidate the PetMeds and PetCareRx brands, reduce duplicative costs, improve inventory and fulfillment efficiency, enhance AutoShip and customer retention, and invest in a unified technology platform, pharmacy systems, analytics and automation.
Management expects to preserve liquidity while funding growth initiatives. Planned actions include supplier negotiations, inventory forecasting, expense reductions, vendor and agency consolidation, expanded third-party logistics and technology-enabled order processing.
- Internal controls: Management and the independent auditor concluded that internal control over financial reporting was not effective as of March 31, 2024. Material weaknesses remained in sales-tax accounting, income-tax and goodwill valuation controls, and IT general controls. The segregation-of-duties weakness was remediated.
- Restatement and tax exposure: Sales-tax liabilities, deferred tax assets and goodwill required correction. Future adjustments may occur as voluntary disclosure agreements, customer exemption documentation and tax assessments are resolved.
- Legal contingency: A putative class action filed in April 2024 alleges misleading “regular” prices and illusory discounts under Pennsylvania law. The Company denies liability and cannot currently estimate the potential loss.
- Management changes: Matthew Hulett resigned as CEO and director on April 29, 2024 and was replaced by Sandra Campos. CFO Christine Chambers entered a transition and separation agreement on May 31, 2024.
- Regulatory risk: The business depends on pharmacy, DEA, FDA, insurance and state licenses. Florida and New York community-pharmacy licenses were scheduled for renewal in February and April 2025, respectively.
- Concentration and competition: Approximately 78.1% of fiscal 2024 product purchases came from seven suppliers, and approximately 49% of sales came from eight states. Competition, pricing pressure, veterinarian resistance and supplier compliance with minimum advertised pricing policies could affect margins and sales.
- Cybersecurity and technology: The Company is migrating systems and does not currently carry cyber insurance. It reported no material cybersecurity incident to date but identified risks involving access controls, change management and third-party service providers.
- Goodwill: Goodwill was $26.7 million. The March 31, 2024 impairment test found no impairment, but estimated fair value exceeded carrying value by approximately 27%, leaving sensitivity to future operating performance and valuation assumptions.
Most Important Facts for Investors to Verify
- Whether fiscal 2025 brand consolidation and cost reductions improve operating margins and restore positive operating cash flow.
- The status and effectiveness of remediation for the remaining internal-control material weaknesses, particularly sales-tax accounting, tax and goodwill valuation, and IT general controls.
- Final outcomes of sales-tax voluntary disclosures, potential assessments, penalties and interest, and the Pennsylvania pricing litigation.
- PetCareRx’s standalone contribution to revenue, gross profit, membership retention and operating expenses after integration.
- Cash utilization, minimum liquidity needs and whether the dividend suspension will remain in effect.
- Customer acquisition cost, reorder trends, AutoShip retention and the sustainability of the improved gross margin.
- Renewal of required pharmacy and insurance-related licenses and the Company’s ability to manage regulatory compliance across jurisdictions.